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High levels of interleukin-6 (IL-6) in the acute stage associated with lung lesions were found in SARS patients. To evaluate the mechanisms
behind this event, we investigated the roles of SARS-CoV proteins in the regulation of IL-6. Results showed that the viral nucleocapsid (N)
protein activated IL-6 expression in a concentration-dependent manner. Promoter analyses suggested that NF-κB binding element was required for
IL-6 expression regulated by N protein. Further studies demonstrated that N protein bound directly to NF-κB element on the promoter. We also
showed that N protein activated IL-6 expression through NF-κB by facilitating the translocation of NF-κB from cytosol to nucleus. Mutational
analyses revealed that two regions of N protein were essential for its function in the activation of IL-6. These results provided new insights into
understanding the mechanism involved in the function of SARS-CoV N protein and pathogenesis of the virus.
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Severe acute respiratory syndrome (SARS) is a life-
threatening form of atypical pneumonia that emerged in 2003,
resulting in 8098 probable cases and 774 deaths around the
world (http://www.who.int/csr/sars). Severe acute respiratory
syndrome-associated coronavirus (SARS-CoV) is the etiologi-
cal agent for the outbreak of SARS (Peiris et al., 2003). Similar
to other coronaviruses in structure, SARS-CoV is an enveloped
virus containing a single-stranded, positive-sense RNA genome
with 29,700 nucleotides in length that encodes for viral proteins
including four structural proteins, spike (S) glycoprotein, matrix
(M) protein, small envelope (E) protein, and nucleocapsid (N)
protein (Marra et al., 2003).
For coronaviruses, the N protein plays important roles during
host cell entry and virus particle assembly and release (Hogue,
1995; Narayanan et al., 2000, 2003). In particular, N protein
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doi:10.1016/j.virol.2007.04.009formation of the helical nucleocapsid (Narayanan et al., 2003).
A similar function of N protein has been found in other viruses,
in addition to coronaviruses (Myers and Moyer, 1997).
However, the mechanism by which N protein facilitates virus
replication is not established. The N protein of SARS-CoV is
422 amino acids long, sharing only 20–30% homology with the
N proteins of other coronaviruses (Marra et al., 2003; Rota et
al., 2003). However, it contains a short lysine-rich sequence
(362-KTFPPTEPKKDKKKKTDEAQ-381) near the carboxyl
terminus, a putative bipartite nuclear localization signal that has
not been found in the N proteins of any other known co-
ronavirus (Marra et al., 2003), suggesting the SARS-CoV
nucleocapsid protein might have novel functions in patho-
genesis. The SARS-CoV N protein has been reported to activate
the activator protein 1 (AP1) signal transduction pathway (He et
al., 2003) and to induce actin reorganization in COS-1 cells
(Sutjit et al., 2004) by forming a dimmer by self-association (He
et al., 2004).
Interleukin-6 (IL-6) is a pleiotropic cytokine that plays
major roles in immunological responses, inflammation, bone
metabolism, neoplasia, and aging (Akira et al., 1993;
Papanicolaou et al., 1998; Erschler and Keller, 2000). IL-6
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and growth factors. It has been reported that activation of IL-6
expression is controlled by the activity of several transcription
factors with known consensus sequences in the IL-6 promoter
region, including IRF-1 (−267 to −254), AP-1 (−283 to
−277), C/EBP (−158 to −145 and −87 to −76), Sp1 (−123 to
−119 and −108 to −104), and NF-κB (−75 to −63) binding
sites (Akira and Kishimoto, 1992; Yan et al., 1995). NF-κB
belongs to the Rel family of transcription factors that form
homo- or heterodimers through the Rel homology domain
(Akira and Kishimoto, 1997; Sen and Baltimore, 1986). In
most cells, NF-κB is present in the cytoplasm bound to a
member of the IκB family of inhibitors (Verma et al., 1995;
Carlotti et al., 2000). Upon activation of the cells by
cytokines, such as TNF-α and IL-1, viruses, bacteria, or
mitogens, IκB is phosphorylated and then rapidly degraded
allowing the translocation of NF-κB to the nucleus where it
binds to specific DNA binding sites.
High serum levels of IL-6 and IL-8 in the acute stage
(cytokine storm) associated with lung lesions were found in
SARS patients (Hsueh et al., 2004). However, the molecular
mechanisms behind this event remain to be determined. In
this study, we investigated the roles of SARS-CoV structural
proteins in the regulation of IL-6 expression in human lung
epithelial cells (A549). In addition, transcription factor
involved in the regulation of IL-6 by the viral N protein
was also studied. This study partially explains the clinical
observation of dramatic cytokine storm and inflammation
responses in SARS patients and provides new insights into
our understanding the molecular mechanisms involved in the
functions of SARS-CoV N protein and pathogenesis caused
by the SARS-CoV.
Results
Nucleocapsid protein of SARS-CoV activates the expression
of IL-6
It has been shown that high serum levels of IL-6 in the acute
stage associated with lung lesions were found in SARS patients
(Hsueh et al., 2004). We were, therefore, interested in evaluating
the molecular mechanism involved in the expression of IL-6
activated by SARS-CoV. A reporter plasmid (pIL6-luc-651)
carrying the luciferase gene under the control of IL-6 promoter
was co-transfected with control plasmid (pCMV-tag2B) or
plasmid (pCMV-tag2B-N, pCMV-tag2B-S, pCMV-tag2B-M, or
pCMV-tag2B-E) containing each of the four viral structural
genes of SARS-CoV, respectively, into human airway epithelial
cells (A549).
Results from luciferase activity assays of transfected cells
revealed that the activity of IL-6 promoter was significantly
stimulated in the presence of N protein, slightly enhanced by the
S protein, and not changed when M or E protein present,
comparing to that of control (Fig. 1A). We also evaluated the
status of N, S, M, and E proteins expressed in transfected A549
cells by western bolt analysis using anti-flag antibody. Results
showed that all four proteins (N, S, M, and E) were expressed intransfected cells, respectively (Fig. 1B). Further study showed
that the level of luciferase activity increased as the concentration
of plasmid pCMV-tag2B-N carrying the N gene increased,
indicting that the activation of IL-6 promoter regulated by N
protein was concentration-dependent (Fig. 1C). However, the
level of luciferase activity remained relatively unchanged when
M, E, or S protein was presented in transfected cells (data not
shown).
To further determine the effect of N protein on the levels
of IL-6 protein and mRNA expressed, two additional
experiments, enzyme-linked immunosorbent assay (ELISA)
and semi-quantitative RT-PCR, were performed. A549 cells
were transfected with plasmid pCMV-Tag2B-N or control
plasmid pCMV-Tag2B. ELISA results from analyses of
transfected cells showed that the level of IL-6 protein was
increased in the presence of the viral N protein, comparing to
that of controls (Fig. 1D). Results from semi-quantitative RT-
PCR also indicated that the N protein could significantly
activate the expression of IL-6 mRNA (Fig. 1E). Thus, all
results from luciferase activity assays, ELISA, and semi-
quantitative RT-PCR were consistent and demonstrated that
the N protein of SARS-CoV activated IL-6 expression in
human airway epithelial cells.
NF-κB binding element is required for N protein to activate
IL-6 expression
Activation of the IL-6 gene relies on many consensus cis-
elements including NF-κB, AP-1, and C/EBP binding sites on
the IL-6 promoter (Keller et al., 1996) (Fig. 2A). Since our
results showed that the viral N protein activates the expression
of IL-6, we further investigated the roles of these cis-regulatory
elements in the activation of IL-6 expression regulated by N
protein. Site-specific mutations or truncated mutations of the
IL-6 promoter were generated and used to construct reporter
plasmids in which the luciferase gene was under the control of
each individual mutant IL-6 promoter.
To determine the activities of these mutant promoters, A549
cells were co-transfected with plasmid pCMV-tag2B-N and
reporter plasmid containing the luciferase gene driven by each
of the mutant IL-6 promoters, respectively. Results from ana-
lysis of site-specific mutants of IL-6 gene promoter showed that
the level of luciferase activity was increased by 5.3-fold, 4-fold,
5-fold, 5.1-fold, 1.3-fold, and 4.9-fold under the control of full
length IL-6 promoter (pIL6-luc-651), or promoters with mu-
tations in cis-regulatory elements AP1a (pIL6-luc-651ΔAP1a),
C/EBPa (pIL6-luc-651ΔC/EBPa), C/EBPb (pIL6-luc-651ΔC/
EBPb), NF-κB (pIL6-luc-651ΔNF-κB), or AP1b (pIL6-luc-
651ΔAP1b), respectively (Fig. 2A). Results from analysis of
truncated mutants of IL-6 gene promoter revealed that the level
of luciferase activity was increased by 5.3-fold, 5-fold, 5.2-fold,
7.9-fold, and 1.2-fold under the control of full length IL-6
promoter (pIL6-luc-651), or four truncated promoters (pIL6-
luc-225, pIL6-luc-100, pIL6-luc-76, pIL6-luc-64), respectively
(Fig. 2B). These results suggested that NF-κB recognition site
was required for the activation of IL-6 promoter regulated by N
protein.
Fig. 1. Determination of roles of SARS-CoV N protein in the activation of IL-6 gene. (A) A549 cells were co-transfected with plasmid pCMV-tag2B-N, pCMV-
tag2B-M, pCMV-tag2B-S, or pCMV-tag2B-E expressing N, M, S, or E protein, respectively, along with the reporter plasmid pIL6-luc-651 in which the luciferase
gene is under the control of IL-6 promoter. The negative control is parental plasmid pCMV-tag2B. Relative luciferase activity was determined by standard
procedures. (B) The expression of N, S, M, or E protein in transfected A549 cells was evaluated by western bolt analysis using anti-flag antibody. (C) A549 cells
were co-transfected with different amount of plasmid pCMV-Tag2B-N as indicated along with the reporter plasmid pIL6-luc-651. Relative luciferase activities were
determined from transfected cells by standard procedures. (D) A549 cells were transfected with plasmid pCMV-Tag2B-N or pCMV-Tag2B. Supernatants of
transfected cells were prepared and concentration of IL-6 protein was determined by ELISA using anti-IL-6 antibody. (E) A549 cells (lane 1) were transfected with
pCMV-Tag2B (lane 2) or pCMV-Tag2B-N (lane 3). The levels of IL-6 mRNA expressed in transfected cells were determined by RT-PCR using primers specific to
IL-6 and the levels of β-actin mRNA produced were measured using primers specific to β-actin. All product bands were visualized and quantified using Gel-Pro
Analyzer. The results were expressed as the mean+S.D. of three independent experiments performed in triplicate.
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of IL-6
Previous studies have reported that N protein activates NF-
κB and such activation is dose-dependent (Liao et al., 2005). Todetermine the roles of N protein and NF-κB in the activation of
IL-6, we measured the effect of NF-κB inhibitor (MG-132) on
the effect of N protein on the activation of IL-6 promoter. Cells
were co-transfected with plasmid (pCMV-tag2B-N) and re-
porter (pIL6-luc-651) and then treated with MG-132 at different
Fig. 2. Functional analysis of cis-regulatory elements involved in the activation of IL-6 promoter regulated by N protein. (A) Diagram of site-specific mutants of IL-6
promoter (left panel) and effects of N protein on the activities of these promoters (right panel). (B) Diagram of truncated mutants of IL-6 promoter (left panel) and
effects of N protein on the activities of these promoters (right panel). A549 cells were co-transfected with plasmid pCMV-Tag2B-N and reporter plasmid carrying the
luciferase reporter gene driven by each of the IL-6 mutant promoters. Promoter activities were determined by measuring the relative luciferase activity in transfected
cells. pCMV-Tag2B was used as a negative control (1-fold). Data are expressed as mean+S.D. of three independent experiments.
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assays revealed that the activity of IL-6 promoter induced by N
protein was gradually inhibited as the concentration of MG-132
increased (Fig. 3A) indicating that NF-κB protein was required
for the activation of IL-6 promoter regulated by the viral N
protein.
The effect of p65, a subunit of NF-κB, on the function of N
protein in terms of activation of IL-6 promoter was also
determined. A549 cells were co-transfected with plasmid
expressing p65 or N protein and the reporter plasmid (pIL6-
luc-651) or the mutant plasmid (pIL6-luc-651ΔNF-κB). Result
from luciferase activity assays showed that the expression of IL-
6 promoter was stimulated in the presence of p65 or N protein
(Fig. 3B, lanes 2 and 4) comparing to that of control (Fig. 3B,
lane 1). The activity of IL-6 promoter reached a highest levelwhen both p65 and N proteins present (Fig. 3B, lane 3)
indicating that p65 and N proteins had a synergetic effect on the
activation of IL-6. However, the NF-κB binding site mutation of
IL-6 promoter (pIL6-luc-651ΔNF-κB) abolished the effect of
p65 and/or N protein on the activation of IL-6 promoter (Fig. 3B,
lanes 5, 6, 7, and 8).
In order to determine the effects of p65 and/or N protein on
the expression of IL-6 protein, A549 cells were co-transfected
with plasmid expressing p65 or N protein. Results from ELISA
of transfected cells demonstrated that N protein (Fig. 3C, lane 3)
or p65 protein (Fig. 3C, lane 5) could stimulate the expression of
IL-6 protein. ELISA result also showed that N protein could
enhance the expression of IL-6 protein activated by the p65 (Fig.
3C, lane 4). This result also suggested that NF-κB and N protein
had a synergetic effect on the activation of IL-6 expression.
Fig. 3. Determination of the role of NF-κB in the expression of IL-6 regulated by
N protein. (A) A549 cells were co-transfected with pCMV-Tag2B-N and pIL6-
luc-651 followed by the treatment with MG-132 at different concentrations as
indicated for 24h. Treated cells were then lysed and luciferase activity was
measured. (B) A549 cells were co-transfected with pIL6-luc-651 (lanes 1–4) or
pIL6-luc-651ΔNF-κB (lanes 5, 6, 7, and 8), pCMV-Tag2B-N (lanes 2, 3, 6,
and 7) or pCMV-Tag2B (lanes 1, 2, 4–6, and 8), and pCMV-Tag2B-p65 (lanes 3,
4, 7, and 8), respectively. Transfected cells were then lysed and luciferase activity
was measured. (C) A549 cells were transfected with pCMV-Tag2B (lanes 2
and 3), or pCMV-Tag2B-N (lanes 3 and 4), or pCMV-Tag2B-p65 (lanes 4 and 5).
Transfected cells were lysed and the levels of IL-6 protein produced were then
measured by ELISA using anti-IL-6 antibody. The results were expressed as
mean+S.D. of three independent experiments.
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nucleus
Localization to the nucleus is a common feature of co-
ronavirus nucleoproteins (Wurm et al., 2001). Analysis of
amino acid sequences revealed that the SARS-CoV N protein
contains a putative nuclear export signal (NES) located at po-sition 220–231 and three putative classical nuclear localization
signals (NLS1, NLS2, and NLS3) located at positions 34–44,
257–265, and 369–390, respectively (Timani et al., 2004).
We initially examined the effect of N protein on the
translocation of p65 from cytosol to nucleus by transfection
of A549 cells with plasmid (pCMV-Tag2B-N) expressing the N
protein or with plasmid (pCMV-Tag2B-M) expressing the M
protein as a control. At 0, 24, and 48 h post-transfection, cytosol
and nucleus fractions were prepared from transfected cells.
Levels of p65 presented were determined by western blot using
anti-p65 antibody. Results clearly revealed that the level of p65
protein was decreased in cytosol and increased in nucleus as the
time of transfection increased in cells transfected pCMV-
Tag2B-N (Fig. 4A). However, the level of p65 protein was
relatively unchanged in cytosol and in nucleus as the time of
transfection increased in cells pCMV-Tag2B-M (Fig. 4B).
These results suggested that N protein facilitates the transloca-
tion of p65 from cytosol to nucleus.
It has been shown that the full-length sequence of NES of N
protein is required for the export of the viral protein out from the
nucleus (Timani et al., 2005). To determine the effect of NES of
N protein on the activation of IL-6, an N protein mutant
(NΔ220-231) was generated in which the NES sequence was
internally deleted. A549 cells were co-transfected with plasmid
(pCMV-Tag2B-NΔ220-231) containing the mutant N gene and
the reporter plasmid (pIL6-luc-651). Results from luciferase
analysis of transfected cells revealed that the level of IL-6
promoter activity was 11-fold and 5.1-fold in the presence of the
mutant N protein (NΔ220-231) and the wild-type protein,
respectively (Fig. 4C). This result suggested that deletion of
nuclear export signal of N protein resulted in the additional
enhancement of IL-6 activation by at least 2-fold.
N protein binds directly to the NF-κB recognition elements on
the IL-6 promoter
Since our results showed that NF-κB regulatory element is
required for the activation of IL-6 regulated by N protein, it is
reasonable for us to assume that SARS-CoV N protein may
function through the binding of N protein to NF-κB regulatory
elements on the IL-6 promoter.
To confirm this speculation, we performed electrophoresis
mobility shift assay (EMSA) to determine protein–DNA
binding between N protein and IL-6 promoter. A549 cells
were transfected with control plasmid pCMV-Tag2B (Fig. 5A,
lanes 1, 2, and 3) or plasmid pCMV-Tag2B-N (Fig. 5A, lanes 4,
5, 7, and 8). Nuclear extracts were prepared from transfected
cells and EMSAwas performed with 4 μg of nuclear extract in
binding buffer. To assure the specific binding of transcription
factors to the probe, unlabeled double-stranded oligonucleotide
competitors were added prior to the addition of labeled probe
(Fig. 5A, lanes 2 and 5). To determine whether N protein was
specific bound to the promoter, rabbit anti-N polyclonal
antibody (Fig. 5A, lanes 1 and 4) or normal rabbit polyclonal
antibody (rabbit IgG) (Fig. 5A, lane 8) was incubated with
nuclear extracts before adding the binding buffer. DNA probes
used in this study were specific for the NF-κB recognition
Fig. 4. Determination of the role of N protein in the translocation of NF-κB and activation of IL-6. (A) A549 cells were transfected with plasmid pCMV-Tag2B-N.
Cytosol and nucleus fractions of transfected cells were prepared at different time as indicated. Levels of cytosolic and nuclear p65 protein and N protein were
determined by western blot using anti-p65 antibody and anti-N antibody, respectively. (B) A549 cells were transfected with plasmid pCMV-Tag2B-M. Cytosol and
nucleus fractions of transfected cells were prepared at different time as indicated. Levels of cytosolic and nuclear p65 protein were determined by western blot using
anti-p65 antibody. (C) A549 cells were co-transfected with reporter plasmid pIL6-luc-651 along with plasmid pCMV-Tag2B-N or plasmid pCMV-Tag2B-MutNΔ220-
231 expressing a mutant N protein (ΔNES) in which a putative nuclear export signal NES located at position 220–231 was deleted. IL-6 promoter activities were
determined by measuring the relative luciferase activity in transfected cells. Data are expressed as mean+S.D. of three independent experiments.
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on nondenaturing polyacrylamide gels and subjected to auto-
radiography. Results from EMSA using NF-κB probes showed
that a specific protein–DNA complex was supershifted in cells
transfected in the presence of N protein and anti-N polyclonal
antibody (Fig. 5A, lane 4).
To further confirm the specific binding of N protein to the
NF-κB recognition element on the IL-6 promoter, chromatin
immunoprecipitation assays (ChIP) were performed. Chromatin
fragments were prepared from A549 cells transfected with
plasmid pCMV-Tag2B-N and immunoprecipitated with specific
rabbit anti-N polyclonal antibody. Two regions (region a: −225
to +13 and region b: −76 to +13) of IL-6 promoter containing
the NF-κB binding sequences were amplified by PCR using
specific primers (Table 1), respectively. Results showed that
PCR products were only produced from DNA isolated fromcells transfected with pCMV-Tag2B-N in the presence of anti-N
antibody (Fig. 5B, lane 4) or directly from input DNA (Fig. 5B,
lane 1), but not detected in the presence of control plasmid (Fig.
5B, lane 2) and normal rabbit polyclonal antibody (rabbit IgG)
(Fig. 5B, lane 4) or without the treatment of anti-N antibody
(Fig. 5B, lane 3). These results demonstrated that the N protein
could specifically bind to the NF-κB recognition site on the IL-6
promoter.
Two regions of N protein are essential for the viral protein to
activate IL-6 gene
For coronaviruses, the nucleocapsid protein plays an im-
portant role during viral packaging, viral core formation, and
viral RNA synthesis (Narayanan et al., 2003). In this study, we
showed that SARS-CoV N protein plays a role in the activation
Table 1
Primers used for generating mutations of IL-6 promoter in this study
AP-1-b-U 5′-AATATTGAGCTGCATGGGAA-3′
AP-1-b-D 5′-TTCCCATGCAGCTCAATATT-3′
C/EBP-b-U 5′-CATTTGTAGTTTCTTTGTTG-3′
C/EBP-b-D 5′-CAACAAAGAAACTACAAATG-3′
IL-6-225-U 5′-CGTGGTACCTAGCCTCAATGA-3′
IL-6-100-U 5′-ATTGGTACCCCCTCACCCTCC-3′
IL-6-76-U 5′-CCGGGTACCGTGGGATTTTC-3′
IL-6-64-U 5′-CAAGGTACCCCCATGAGTCT-3′
IL-6-651-D 5′-AGTACCGGAATGCCAAGCTT-3′
Fig. 5. Determination of interaction between SARS-CoV N protein and IL-6
promoter. (A) Electrophoretic mobility shift assay (EMSA) was performed with
nuclear extracts of A549 cells transfected with (lanes 4, 5, 7, and 8) or without
(lanes 1–3, and 6) the N gene. NF-κB probes from nucleotides −76 to −63 were
labeled and added to the reactions (lanes 1, 2–5, 7, and 8). Unlabeled double-
stranded oligonucleotide competitors of NF-κB probe were added during pre-
incubation prior to the addition of probes (lanes 2 and 5). For supershift
experiments, rabbit anti-N polyclonal antibody (lanes 1 and 4) or normal rabbit
polyclonal antibody (rabbit IgG) (lane 8) were incubated with nuclear extracts
before adding to the reactions. Samples were electrophoresed on 5%
nondenaturing polyacrylamide gel and visualized by autoradiography. Arrows
indicate the super-shifted protein–DNA complex, shift band, and free probe.
Lane 6: black space. (B) Chromatin immunoprecipitation assay (ChIP) was
performed with A549 cells transfected with control pCMV-Tag2B (lane 2) or
pCMV-Tag2B-N (lanes 1, 3, 4, and 5). Immunoprecipitated complexes were
collected, subjected to PCR amplification, and separated by agarose gel
electrophoresis. The IL-6 promoter regions (−225 to +13) and (−76 to +13)
were amplified by PCR using specific primers (IL-6-225U and IL-6-651D or IL-
6-76U and IL-6-651D), respectively. Lane 1: input DNA as positive control.
Lane 4: normal rabbit polyclonal antibody (rabbit IgG) as a negative control.
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protein in the activation of IL-6 expression, we constructed
several deletion mutants of the N protein and analyzed the
functions of these mutants in the activation of IL-6.
To evaluate the function of each mutant, A549 cells were co-
transfected with plasmid carrying the N gene mutant and the
reporter plasmid. Ability of truncated N proteins to activate IL-6
expression was measured by luciferase activity assays in trans-fected cells (Fig. 6A). Results revealed that deletion of 61 amino
acids (N61-422) or 86 amino acids (N86-422) from the N
terminus of N protein resulted in a slight increase of IL-6
promoter activity. However, further deletion of 96 amino acids
(N96-422) from the N terminus of the viral protein abolished its
ability to activate IL-6 expression. These results suggested that
the region from amino acids 86 to 96 of N protein was essential
for the viral protein to activate the expression of IL-6 gene.
In addition, results showed that deletion of amino acids from
341 to 422 of N protein resulted in the loss of function in the
activation of IL-6 and that both N- and C-terminus deletions
(N86-341) of N protein abolished the ability of the viral protein
to activate IL-6 expression. These results demonstrated that the
C-terminus from amino acids 341 to 422 of N protein was also
essential for the viral protein to activate the expression of IL-6
gene.
The ability of each plasmid carrying truncated N gene to
produce corresponding mutant N protein was confirmed by
western bolt analysis using anti-N protein antibody (Fig. 6B).
Results showed that all truncated N proteins were produced
with their sizes as expected.
Discussion
SARS is an emerged infectious disease characterized by
persistent fever, respiratory symptoms with lung consolidation,
lymphopenia, and respiratory failure in life-threatening cases.
IL-6 is a pleiotropic cytokine that plays a major role in the
host's response to injury or infection (Snick, 1990). IL-6
expression is tightly regulated and can be induced in
macrophages, synovial fibroblasts, endothelial cells, and other
cell types. IL-6 plays a crucial role in autoimmune diseases
because abnormally high quantities of IL-6 are found in several
autoimmune diseases (Hirano, 1992). The elevations of IL-6
and cytokines have been found in the plasma of SARS patients
(Hsueh et al., 2004), and can induce the hyperinnate
inflammatory response due to the SARS-CoV invasion of the
respiratory tract.
It is important to investigate the roles of SARS-CoV in the
induction of cytokine, such as IL-6 in the lung cells, which may
be the cause or consequence of pulmonary inflammation and
immune hyperreactivity in SARS. In this study, we showed that
among all SARS-CoV structural proteins (N, S, E, and M)
tested (Fig. 1B), only the N protein significantly induced the
activation of IL-6 promoter in human airway epithelial cell
cultures (Fig. 1A) and such activation was in a dosage-
Fig. 6. Functional analysis of deletion mutants of SARS-CoVN protein. (A) Diagram of N protein mutants (left panel) and functional analyses of mutant proteins (right
panel). A549 cells were co-transfected with the reporter plasmid pIL6-luc-651 along with plasmid pCMV-Tag2B-N or plasmid containing individual mutant N gene.
The effects of each N protein on the activation of IL-6 promoter were determined by measuring luciferase activities of transfected cells. Values correspond to an
average of at least three independent experiments. (B) The status of N protein and its mutants expressed in the transfected A549 cells were determined by western bolt
using anti-N protein antibodies.
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protein activates the IL-6 promoter (Fig. 1D) and induces IL-6
protein production (Fig. 1E) in A549 cells. These results were
consistent with previous clinical findings (Hsueh et al., 2004)
and further demonstrated that N protein is, at lease partially,
responsible for the induction of IL-6 gene expression.
Studies of other coronavirus have reported that the nu-
cleocapsid proteins have a variety of functional activities (He et
al., 2004). It has been suggested recently that N protein is a two-
domain protein, with the N-terminal from amino acids 50 to 150
as the RNA-binding domain. Our recent results indicated that N
protein activates COX-2 gene expression by binding either
directly or indirectly to NF-κB and C/EBP regulatory elements
on COX-2 promoter (Yan et al., 2006). Previous studies of the
IL-6 promoter indicated optimal IL-6 activation correlated with
the NF-κB sites both in vivo and in vitro. IL-6 gene activation
involves the rapid transport of preexisting p65 to the nucleus
after release from a complex with IκB in the cytosol (Lieberman
and Baltimore, 1990).
It is reasonable for us to speculate that N protein activates IL-6
gene expression by binding directly or indirectly to NF-κB
regulatory element on IL-6 promoter. In this study, we
demonstrated that NF-κB regulatory element was essential for
N protein function in the induction of IL-6 expression since
mutation of such binding site eliminated the activation of IL-6induced by N protein (Fig. 2). Such mutation of IL-6 promoter
also abolished the effect of p65 (a subunit of NF-κB) and/or N
protein on the activation of IL-6 promoter (Figs. 3B and C). In
addition, results from electrophoresis mobility shift assay (EMSA)
(Fig. 5A) and chromatin immunoprecipitation assays (ChIP) (Fig.
5B) demonstrated that SARS-CoV N protein could bind directly
to NF-κB regulatory elements on IL-6 gene promoter.
Previous studies have reported that N protein can activate
transcriptional factor NF-κB and such activation is dose-
dependent (Liao et al., 2005). In this study, we further
demonstrated that the viral N protein is required for the
activation of NF-κB in the regulation of IL-6 expression. Our
results revealed that the activity of IL-6 promoter induced by N
protein was eliminated by the presence of NF-κB inhibitor, MG-
132 (Fig. 3A). In addition, we also showed that the viral N
protein and the host transcription factor p65 protein had a
synergetic effect on the activation of IL-6 (Figs. 3B and C), such
effect was abolished when NF-κB recognition site was mutated
(Fig. 3B). Finally, we found that N protein facilitates the
translocation of p65 from cytosol to nucleus (Fig. 4A).
However, the detailed mechanisms involved in the activation
of IL-6 expression regulated by the viral N protein and the
transcriptional factor NF-κB need to be further investigated.
Localization to the nucleolus is a common feature of
coronavirus N proteins. This feature helps disrupt host cell
Table 2
Primers used for amplification of genes of SARS-CoV in this study
Nu 5′-AGCTGGATCCATGTCTGATAATGGACCCCAATCAAAC-3′
Nd 5′-AGCTGAATTCCATCATGAGTGTTTATGCCTGAGT-3′
Mu 5′-AGCTGGATCCGCTTATCATGGCAGACAACGGTACT-3′
Md 5′-AGCTGAATTCCATCTGTTGTCACTTACTGTACTAGC-3′
Eu 5′-AGCTGGATCCATGTACTCATTCGTTTCGGAAGAAAC-3′
Ed 5′-AGCTGAATTCTTAGTTCGTTTAGACCAGAAGATC-3′
Su 5′-AGCTGGATCCACATGTTTATTTTCTTATTATTTCTTAC-3′
Sd 5′-AGCTGAATTCACTGGCTGTGCAGTAATTGATCC-3′
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translation of viral proteins (Wurm et al., 2001). SARS-CoV N
protein localized to the cytoplasm and nucleus of mammalian
cells (Timani et al., 2005). Our results showed that the C-
terminus (from amino acids 341 to 422) of N protein was
essential for the viral protein to activate the expression of IL-6
gene, since deletion of this region resulted in the loss of function
in the activation of IL-6 (Fig. 6). Because this region contains a
putative nuclear localization signal (NLS3), the failure of this
mutation to activate IL-6 expression might be due to the loss of
its ability to target to the nucleus.
Analysis of truncated N proteins also revealed that the region
from amino acids 86 to 96 of N protein was essential for the
viral protein to activate the expression of IL-6 gene (Fig. 6A).
This result was in agreement with the finding that through
multi-alignment of total 19 sequences of the coronavirus N
proteins including that of SARS-CoV, one conserved structural
region at amino acids 81 to 140 was found to perform critical
functions (Wang et al., 2003).
The biological functions of coronavirus N protein are
thought to participate in the replication and transcription of
viral RNA and to interfere with the cell cycle of host cells
(Parker and Masters, 1990; Kuo and Masters, 2002). The N
proteins of many coronaviruses are highly immunogenic and
abundantly expressed during infection (Liu et al., 2001;
Narayanan et al., 2003). However, its intracellular effects on
host gene regulation remain largely unknown. The cytoplasmic
localization of SARS-CoV N protein is reported recently
(Chang et al., 2004), suggesting that N protein may interact with
unknown cytoplasmic and nuclear proteins to regulate host gene
expression.
Our results demonstrated that SARS-CoV N protein
interacted with the host transcriptional factor NF-κB to regulate
IL-6 expression, which may partially explain the clinical
observation of dramatic cytokine storm and inflammation
responses in SARS patients. These results provide new insights
into our understanding of the mechanism involved in the
functions of SARS-CoV N protein and pathogenesis of SARS-
CoV. In addition, these data would also provide new insights
into the development of novel vaccine and therapeutics for the
prevention and treatment of SARS.
Materials and methods
Cell culture
Human airway epithelial cell line (A549) was cultured in
Ham's F12K medium (Sigma), supplemented with 10% fetal
bovine serum, 100 μg/ml penicillin, and 100 μg/ml streptomy-
cin at 37 °C in a 5% CO2 incubator.
Plasmid construct
A plasmid (pIL6-luc-651) containing a 651-bp fragment of
the human IL-6 gene promoter located directly upstream of the
transcriptional start site and its site-specific mutants pIL6-luc-
651ΔC/EBPa, pIL6-luc-651ΔNF-κB, and pIL6-luc-651ΔAP-1a were kindly provided by Oliver Eickelberg (University of
Giessen) (Eickelberg et al., 1999). The AP-1 site b and C/EBP
site b were mutated by using QuickChange site-directed muta-
genesis kit (Stratagene). The AP-1b site consensus sequence
(positions −61 to −55, 5′-TGAGTCT-3′) was changed to 5′-
TGCAGCT-3′ (Baccam et al., 2003). The C/EBPb site
consensus sequence (positions −86 to −76, 5′-CTTAT-
CAAAT-3′) was changed to 5′-ACTACAAACT-3′ (Galien et
al., 1996). The truncated mutants of IL-6 promoter mIL6-luc-
225, mIL6-luc-100, mIL6-luc-76, andmIL6-luc-64 were created
by using specific primers (Table 1). Site-specific mutants and
truncated mutants of IL6 promoter were also sub-cloned into the
luciferase expression vector to yield plasmids, pIL6-luc-
651ΔAP-1b and pIL6-luc-651ΔC/EBPb, pIL6-luc-225, pIL6-
luc-100, pIL6-luc-76, and pIL6-luc-64, respectively.
Four viral structural proteins (N, M, S, and E) of SARS-CoV
strain WHU (GenBank Accession No. AY394850) were amp-
lified by RT-PCR from RNA isolated previously from SARS-
CoV infected Vero E6 cells (Zhu et al., 2005) using cor-
responding primers listed in Table 2. The PCR products were
cloned intoEcoRI andBamHI sites of pCMV-tag2B (Stratagene)
to generate plasmid pCMV-tag2B-N, pCMV-tag2B-M, pCMV-
tag2B-S, and pCMV-tag2B-E, respectively. The internal dele-
tion of the N gene (MutNΔ220-231) was performed by using
QuikChange site-directed mutagenesis kit (Stratagene), and its
truncation mutants N1-422, N1-341, N61-422, N86-422, N96-
422, and N86-341 were amplified by PCR using corresponding
primers listed in Table 3. All mutant N genes were cloned into
EcoRI andBamHI sites of pCMV-tag2B (Stratagene) to generate
plasmids pCMV-tag2B-NΔ220-231, pCMV-tag2B-N1-422,
pCMV-tag2B-N1-341, pCMV-tag2B-N61-422S, pCMV-
tag2B-N86-422, pCMV-tag2B-N96-42, and pCMV-tag2B-
N86-341, respectively. The eukaryotic expression plasmid
pCMV-tag2B-p65 carrying the coding regions of p65 under
control of the CMV promoter was a gift of Hongbin Shu
(Wuhan University, China). All constructs were verified by
DNA sequencing.
Generation of polyclonal antisera
Subcloning of N gene into prokaryotic expression vector,
expression and purification of N protein were described
previously (Timani et al., 2004). New Zealand rabbits were
kept in conventional conditions and were handled in compli-
ance with Wuhan University (Wuhan, China) guidelines for
animal care and use. Rabbit was immunized with 0.1–0.2 mg of
Table 3
Primers used for generating mutations of the N gene in this study
MutNΔ220-231-U 5′-GGCTAGCGGAGGTGGTGAAACTGCCGAGAGCAAAGTTTCTGGTAAAGGCC-3′
MutNΔ220-231-D 5′-GGCCTTTACCAGAAACTTTGCTCTCGGCAGTTTCACCACCTCCGCTAGCC-3′
N1-341-D 5′-CTTAAGGGCATCCAATTTAATGGCT-3′
N61-422-U 5′-CCGGATCCAAGGAGGAACTTAGATTC-3′
N86-422-U 5′-AAGGATCCTACTACCGAAGAGCTAC-3′
N96-422-U 5′-AAGGATCCGCAAAATGAAAGAGCTC-3′
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neously at multiple sites on its back. Booster injections were
given 2 weeks and 4 weeks later. Blood was drown from the
rabbit at 5 weeks following the immunization, the blood was
allowed to clot at 4 °C, and the antiserum was recovered by
centrifugation at 5000×g for 10 min at 4 °C. A controlled serum
was done by injecting normal saline at the same conditions.
Transfection and luciferase assays
Co-transfection of luciferase reporter plasmid with relevant
recombinant plasmids into cells was carried out by mixing
0.2 μg of reporter plasmid and 0.4 μg testing plasmids with 2 μl
SofastTM transfection reagents (Xiamen Sunma Biotechnology
Co, Ltd.). The mixture was then added to each well of 24-well
plates with A549 cells growing at 70% confluence. After
incubation for 24 h, the cells were harvested for luciferase
activity assays.
Semi-quantitative RT-PCR analysis
Semi-quantitative RT-PCR analysis was performed to de-
termine IL-6 mRNA level. After 24 h post-transfection, total
RNAwas isolated from transfected cells using a TRIzol reagent
(Invitrogen), and cellular RNA was amplified by reverse-
transcribed PCR with a random primer and then amplified by
PCR using IL-6 specific primers listed in Table 4. β-actin
primer set was used as an internal control. The PCR products
were analyzed by electrophoresis on 1% agarose gel containing
ethidium bromide. All product bands were visualized and
quantified using Gel-Pro Analyzer (Beijing Junyi-Dongfang
Electrophoresis instrument Co., Ltd., China).
Enzyme-linked immunosorbent assay (ELISA)
The level of IL-6 protein produced was assessed by ELISA.
After transfection, secreted IL-6 protein was quantified in
100 μl culture supernatants using an IL-6 ELISA test (Jingmei
Biotech, China) as recommended by the supplier.Table 4
Sequences of primers for RT-PCR and EMSA
β-actin-U 5′-ATGATATCGCC GCGCTCG-3′
β-actin-D 5′-CGCTCGGTGAGGATCTTCA-3′
IL-6mRNA-U 5′-AGCAAAGAGGCACTGGCAGAAAACA-3′
IL-6mRNA-D 5′-AGAAGAAGGAATGCCCATTAACAAC-3′
NF-κB probe-U 5′-CAAATGTGGGATTTTCCCATGA-3′
NF-κB probe-D 5′-TCATGGGAAAATCCCACATTTG-3′Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation assay was done as pre-
viously described with slight modifications (Wu et al., 2003;
Yan et al., 2006). Monolayer of A549 cells (70% confluent) was
incubated for 24 h after transfection, and then formaldehyde
was added to the culture medium to a final concentration of 1%.
The cells were then washed twice in PBS, scraped, and lysed in
lysis buffer (1% SDS, 10 mM Tris–HCl, pH 8.0, 1 mM PMSF,
50 mg/ml of both aprotinin, and leupeptin) for 10 min on ice.
The lysates were sonicated on ice and the debris was removed
by centrifugation at 12,000 rpm for 15 min at 4 °C. One-fourth
of the supernatant was used as DNA input control. The
remaining supernatant was diluted 10-fold with dilution buffer
(0.01% SDS, 1% Triton X-100, 1 mM EDTA, 10 mM Tris–
HCl, pH 8.0, and 150 mM NaCl) and incubated with antibody
against N protein overnight at 4 °C. Immunoprecipitated com-
plexes were collected using protein A/G agarose beads. The
pellets were washed with dialysis buffer (2 mM EDTA, 50 mM
Tris–HCl, pH 8.0). Samples were incubated at 67 °C for 5 h to
reverse formaldehyde crosslink. DNA was precipitated with
ethanol and extracted three times with phenol/chloroform.
Finally, pellets were resuspended in TE buffer and subjected to
PCR amplification using IL-6 promoter specific detection
primer (Table 1). The PCR products were resolved by agarose
gel electrophoresis.
Western blot analysis
Whole cell lysates were prepared by lysing A549 cells with
PBS pH 7.4 containing 0.01% Triton-100, 0.01% EDTA, and
10% cocktail protease inhibitor (Roche, Germany). The
cytosolic and nuclear protein fractions were separated as
described. Cells were washed with ice-cold PBS and collected
by centrifugation and the pellets were resuspended in hypotonic
buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.5 mM DTT,
10% protease cocktail inhibitor) for 15 min on ice, and vortexed
for 10 s. Nuclei were pelleted by centrifugation at 13,000 rpm
for 1 min. Supernatants containing cytosolic proteins were
collected. Lysates were centrifuged at 13,000 rpm for 10 min.
The supernatants were boiled for 5 min with equal volumes of
2× gel loading buffer (100 mM Tris, 10% β-mercaptoethanol,
20% glycerol, 4% SDS, 2 mg/ml bromophenyl blue). One
hundred micrograms of cultured cell lysates was electrophor-
esed in 12% SDS-PAGE gel and transferred to a nitrocellulose
membrane. Nonspecific IgGs were blocked with 5% nonfat
dried milk before being incubated with a rabbit polyclonal anti-
N protein antibody or mouse monoclonal anti-NF-κB antibody
334 X. Zhang et al. / Virology 365 (2007) 324–335(Santa Cruz). Protein bands were detected using SuperSignal
Chemiluminescent (Pierce, IL).
Electrophoretic mobility shift assay (EMSA)
EMSA was performed as described previously with some
modification (Liu et al., 2007). Cells were washed with cold
PBS twice and scraped into 1 ml of cold PBS. Cells were
harvested by centrifugation for 15 s and incubated in 2 packed
cell volumes of buffer A (10 mM HEPES, pH 8.0, 0.5%
Nonidet P-40, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and
200 mM sucrose) for 5 min at 4 °C with flicking the tube. The
crude nuclei were collected by centrifugation for 30 s; pellets
were rinsed with buffer A, resuspended in 1 packed cell volume
of buffer B (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 420 mM
NaCl, 0.2 mM EDTA, and 1.0 mM DTT), and incubated on a
rocking platform for 30 min at 4 °C. Nuclei were clarified by
centrifugation for 5 min, and the supernatants were diluted 1:1
with buffer C (20 mM HEPES, pH 7.9, 100 mM KCl, 0.2 mM
EDTA, 20% glycerol, 1 mM DTT). Cocktail protease inhibitor
tablets were added to each type of buffer. Nuclear extracts were
frozen in liquid N2 and stored at −70 °C until use. NF-κB
oligonucleotides were synthesized by Takara (Takara Biotech
Co. Ltd., Japan) based on the cognate human IL-6 promoter
sequence (Table 4). The complimentary oligonucleotides were
annealed and purified according to the manufacture's protocol.
Each probe was end-labeled with [γ32P] ATP using T4
polynucleotide kinase (Takara biotech). EMSA was performed
by incubating 2 μg of nuclear extract with a labeled probe
(15,000 cpm, 10 fmol) in binding buffer (4 mM Tris–HCl,
12 mM HEPES–KOH, pH 7.9, 60 mM KCl, 12% glycerol,
0.5 mM EDTA, and 1 mM DTT) containing 1 μg of poly(dI
−dC) for 25 min at room temperature. To assure the specific
binding of transcription factors to the probe, the probe was
chased by 100-fold molar excess of cold wild-type. For
supershift experiments, 2 μg of purified polyclonal antibody
was incubated with nuclear extracts on ice for 30 min before
adding to the binding buffer. Samples were electrophorased on
5% nondenaturing polyacrylamide gel with running buffer
(0.25× TBE containing 22.5 mM Tris–borate, 0.5 mM EDTA),
and the gels were dried and subjected to autoradiography.
Statistical analysis
All of the experiments were reproducible and were carried
out in duplicates or quadruplicates. Each set of experiments was
repeated at least three times with similar results and a
representative one is shown. The results are presented at the
means±S.D. Student's t-test for paired samples was used to
determine statistical significance. Differences were considered
statistically significant at a value of P≤0.05.
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